Trial · NCT02899195

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

NCT02899195, Phase 2, Completed, PrECOG, LLC.; results first posted 2021-04-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma. Trials, record NCT02899195. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02899195

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
NCT number: NCT02899195
Status: Completed
Phases: Phase 2
Enrollment: 55 participants, actual
Lead sponsor: PrECOG, LLC.
Conditions: Mesothelioma, Pleural Mesothelioma
Interventions: Durvalumab
First posted: 2016-09-14
Last updated: 2023-07-05
Results first posted: 2021-04-06

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival (OS)	From randomization until death, up to 32 months	Overall survival (OS) is defined as the time from randomization to death from any cause. Patients that have not had an event reported at analysis will be censored at their date of last follow-up.
Secondary	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03	Up to 15 months from start of treatment	Number of participants with abnormal laboratory values and/or adverse events related to treatment.
Secondary	Progression-Free Survival (PFS)	From randomization until disease progression or death from any cause, up to 32 months	Progression-free survival (PFS) is defined as the time from randomization to documented disease progression or death from any cause, whichever occurs first. Patients who have not experienced an event of interest by the time of analysis will be censored at the date they are last known to be alive and progression-free.
Secondary	Time to Progression (TTP) on Durvalumab	From time concurrent treatment started until progression, up to 32 months	TTP measured from the time concurrent treatment with chemotherapy/durvalumab begins until radiologic or clinical progression is noted.
Secondary	Objective Response Rate (ORR)	From randomization until end of treatment, up to 15 months	ORR assessed in accordance with RECIST 1.1 (modified for malignant mesothelioma).

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival (OS)	From randomization until death, up to 32 months	All eligible and treated patients	months	MEDIAN
SECONDARY	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03	Up to 15 months from start of treatment	treated population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Progression-Free Survival (PFS)	From randomization until disease progression or death from any cause, up to 32 months	Eligible and treated population	month	MEDIAN
SECONDARY	Time to Progression (TTP) on Durvalumab	From time concurrent treatment started until progression, up to 32 months	Eligible and treated patients	months	MEDIAN
SECONDARY	Objective Response Rate (ORR)	From randomization until end of treatment, up to 15 months	Eligible and treated patient population	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Survival (OS)	Concurrent Durvalumab Then Maintenance Durvalumab	20.4	95% Confidence Interval 13.0 to 28.5	months
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03	Concurrent Durvalumab Then Maintenance Durvalumab	36		Participants
Progression-Free Survival (PFS)	Concurrent Durvalumab Then Maintenance Durvalumab	6.7	95% Confidence Interval 6.1 to 8.4	month
Time to Progression (TTP) on Durvalumab	Concurrent Durvalumab Then Maintenance Durvalumab	6.8	95% Confidence Interval 6.2 to 8.4	months
Objective Response Rate (ORR)	Concurrent Durvalumab Then Maintenance Durvalumab	31		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Concurrent Durvalumab	STARTED	Concurrent Durvalumab Then Maintenance Durvalumab	55
Concurrent Durvalumab	COMPLETED	Concurrent Durvalumab Then Maintenance Durvalumab	44
Concurrent Durvalumab	NOT COMPLETED	Concurrent Durvalumab Then Maintenance Durvalumab	11
Maintenance Durvalumab	STARTED	Concurrent Durvalumab Then Maintenance Durvalumab	44
Maintenance Durvalumab	COMPLETED	Concurrent Durvalumab Then Maintenance Durvalumab	10
Maintenance Durvalumab	NOT COMPLETED	Concurrent Durvalumab Then Maintenance Durvalumab	34

Source ClinicalTrials.gov

Adverse events106

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	Concurrent Durvalumab Then Maintenance Durvalumab	20	55
other	Hyperthyroidism	Endocrine disorders	Concurrent Durvalumab Then Maintenance Durvalumab	3	55
other	Hypothyroidism	Endocrine disorders	Concurrent Durvalumab Then Maintenance Durvalumab	8	55
other	Dry eye	Eye disorders	Concurrent Durvalumab Then Maintenance Durvalumab	7	55
other	Lacrimation increased	Eye disorders	Concurrent Durvalumab Then Maintenance Durvalumab	4	55
other	Abdominal distension	Gastrointestinal disorders	Concurrent Durvalumab Then Maintenance Durvalumab	3	55
other	Abdominal pain	Gastrointestinal disorders	Concurrent Durvalumab Then Maintenance Durvalumab	4	55
other	Constipation	Gastrointestinal disorders	Concurrent Durvalumab Then Maintenance Durvalumab	27	55
other	Diarrhoea	Gastrointestinal disorders	Concurrent Durvalumab Then Maintenance Durvalumab	13	55
other	Gastrooesophageal reflux disease	Gastrointestinal disorders	Concurrent Durvalumab Then Maintenance Durvalumab	5	55

1 to 10 of 106Source ClinicalTrials.gov

See all 106 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Concurrent Durvalumab Then Maintenance Durvalumab	33	55
Total, other adverse events	Concurrent Durvalumab Then Maintenance Durvalumab	55	55
Total, serious adverse events	Concurrent Durvalumab Then Maintenance Durvalumab	36	55

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
34499875	DERIVED	PubMed
34750557	RESULT	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02899195

GET https://conductscience.org/api/trials/v1/NCT02899195/events?page=2

API reference For AI assistants